Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis
- PMID: 24937432
- PMCID: PMC4071409
- DOI: 10.1172/JCI74783
Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis
Abstract
Activation and accumulation of cardiac fibroblasts, which result in excessive extracellular matrix deposition and consequent mechanical stiffness, myocyte uncoupling, and ischemia, are key contributors to heart failure progression. Recently, endothelial-to-mesenchymal transition (EndoMT) and the recruitment of circulating hematopoietic progenitors to the heart have been reported to generate substantial numbers of cardiac fibroblasts in response to pressure overload-induced injury; therefore, these processes are widely considered to be promising therapeutic targets. Here, using multiple independent murine Cre lines and a collagen1a1-GFP fusion reporter, which specifically labels fibroblasts, we found that following pressure overload, fibroblasts were not derived from hematopoietic cells, EndoMT, or epicardial epithelial-to-mesenchymal transition. Instead, pressure overload promoted comparable proliferation and activation of two resident fibroblast lineages, including a previously described epicardial population and a population of endothelial origin. Together, these data present a paradigm for the origins of cardiac fibroblasts during development and in fibrosis. Furthermore, these data indicate that therapeutic strategies for reducing pathogenic cardiac fibroblasts should shift from targeting presumptive EndoMT or infiltrating hematopoietically derived fibroblasts, toward common pathways upregulated in two endogenous fibroblast populations.
Figures
Comment in
-
Cardiac fibroblasts in pressure overload hypertrophy: the enemy within?J Clin Invest. 2014 Jul;124(7):2850-3. doi: 10.1172/JCI76628. Epub 2014 Jun 17. J Clin Invest. 2014. PMID: 24937423 Free PMC article.
-
Targeting cardiac fibroblasts: the pressure is on.Cell Cycle. 2014;13(17):2647-8. doi: 10.4161/15384101.2014.954212. Cell Cycle. 2014. PMID: 25486346 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
Grants and funding
- HL066100/HL/NHLBI NIH HHS/United States
- R01 HL106968/HL/NHLBI NIH HHS/United States
- HL119967/HL/NHLBI NIH HHS/United States
- R01 HL082902/HL/NHLBI NIH HHS/United States
- R01 CA095287/CA/NCI NIH HHS/United States
- U01 HL107442/HL/NHLBI NIH HHS/United States
- R01 DK099205/DK/NIDDK NIH HHS/United States
- DP1 HL117649/HL/NHLBI NIH HHS/United States
- HL-117649/HL/NHLBI NIH HHS/United States
- R01 HL066100/HL/NHLBI NIH HHS/United States
- P30 NS047101/NS/NINDS NIH HHS/United States
- R01 HL119967/HL/NHLBI NIH HHS/United States
- R01 AA028550/AA/NIAAA NIH HHS/United States
- T32 HL007444/HL/NHLBI NIH HHS/United States
- P50 AA011999/AA/NIAAA NIH HHS/United States
- HL106968/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
